High Apolipoprotein B- Potential Risk Factor for CVD: Latest Indian Experience

Elevated levels of apolipoprotein B is a potential risk factor for cardiovascular disease (CVD) among Indians, a recent study has reported. The association between high Apo B levels & LDL-C indicates a potential risk factor for CVD.

The research has been published in the July 2024 issue of International Journal of Scientific Research. This cross-sectional observational study included 69 participants. 

Here are some of the key observations from this study:

• Participants aged 36-50 years exhibited significantly higher mean levels of apolipoprotein B compared to those aged ≤35 years and those over 50 years. 

Each 10 mg/dl reduction in Apo B leads to a reduction in coronary heart disease by 9% & major CVD risk by 6%¹. Rosuvastatin 40 mg offers a significant reduction in Apo B by 37%².

The study highlights the burden of high Apo B levels as a CV risk factor, emphasizing the need for monitoring and managing Apo B levels to alleviate CVD risk in clinical practice.

References:

1) Robinson JG, Wang S, Jacobson TA. Meta-analysis of comparison of effectiveness of lowering apolipoprotein B versus low-density lipoprotein cholesterol and nonhigh-density lipoprotein cholesterol for cardiovascular risk reduction in randomized trials. Am J Cardiol. 2012 Nov 15;110(10):1468-76. doi: 10.1016/j.amjcard.2012.07.007. Epub 2012 Aug 17. PMID: 22906895.

2) Pitt B, Loscalzo J, Monyak J, Miller E, Raichlen J. Comparison of lipid-modifying efficacy of rosuvastatin versus atorvastatin in patients with acute coronary syndrome (from the LUNAR study). Am J Cardiol. 2012 May 1;109(9):1239-46. doi: 10.1016/j.amjcard.2011.12.015. Epub 2012 Feb 21. PMID: 22360820.

3) Understanding The Correlation Between Apolipoprotein B And Ldl Cholesterol, Sheetal Kamat, Mohd Shahid, Lalit Kumar Garg, Santosh Revankar, International Journal Of Scientific Research 2024;13(7):1-3